Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has issued an announcement.
Recce Pharmaceuticals Ltd has announced a pro-rata non-renounceable entitlement offer to raise approximately $10.8 million, aimed at funding Phase III clinical trials and other development programs. The offer is available to eligible shareholders in specific regions, while ineligible shareholders have been notified of their exclusion due to cost and regulatory considerations. The funds will support trials in Indonesia and Australia, as well as additional clinical activities and working capital, positioning the company for potential revenue generation in 2026.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a biotechnology company focused on developing new classes of synthetic anti-infectives. Their primary products target serious infections and diseases, with a market focus on innovative medical solutions.
YTD Price Performance: -39.58%
Average Trading Volume: 206,124
Technical Sentiment Signal: Buy
Current Market Cap: A$78.45M
For a thorough assessment of RCE stock, go to TipRanks’ Stock Analysis page.